Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35918   clinical trials with a EudraCT protocol, of which   5893   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-002236-24
    Sponsor's Protocol Code Number:261302
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-09-23
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2013-002236-24
    A.3Full title of the trial
    A Phase 3b Continuation study of the Safety and Efficacy of PEGylated
    Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in
    Previously Treated Patients with Severe Hemophilia A
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of the Safety and Effectiveness of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prevention of Bleeding in Previously Treated Patients with Severe Hemophilia A (a blood clotting disorder).
    A.3.2Name or abbreviated title of the trial where available
    PEGylated rFVIII (BAX 855) in Hemophilia A
    A.4.1Sponsor's protocol code number261302
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01945583
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/72/2013
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBaxter Innovations GmbH
    B.1.3.4CountryAustria
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBaxter Innovations GmbH
    B.4.2CountryAustria
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBaxter Innovations GmbH
    B.5.2Functional name of contact pointMichal Chotar
    B.5.3 Address:
    B.5.3.1Street AddressIndustriestrasse 67
    B.5.3.2Town/ cityVienna
    B.5.3.3Post codeA-1221
    B.5.3.4CountryAustria
    B.5.6E-mailmichal_chotar@baxter.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePEGylated rFVIII
    D.3.2Product code BAX 855 500IU/vial
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot applicable
    D.3.9.2Current sponsor codeBAX 855
    D.3.9.3Other descriptive nameBAX 855 (PEGYLATED RFVIII)
    D.3.9.4EV Substance CodeSUB90763
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeRecombinant product with covalently bound polyethyleneglycol.
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePEGylated rFVIII
    D.3.2Product code BAX 855 1000IU/vial
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot applicable
    D.3.9.2Current sponsor codeBAX 855
    D.3.9.3Other descriptive nameBAX 855 (PEGYLATED RFVIII)
    D.3.9.4EV Substance CodeSUB90763
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeRecombinant product with covalently bound polyethyleneglycol.
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePEGylated rFVIII
    D.3.2Product code BAX 855 250IU / vial
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot Applicable
    D.3.9.2Current sponsor codeBAX 855
    D.3.9.3Other descriptive nameBAX 855 (PEGYLATED RFVIII)
    D.3.9.4EV Substance CodeSUB90763
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeRecombinant product with covalently bound polyethyleneglycol
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePEGylated rFVIII
    D.3.2Product code BAX 855 2000IU / vial
    D.3.4Pharmaceutical form Powder and solution for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNot applicable
    D.3.9.2Current sponsor codeBAX 855
    D.3.9.3Other descriptive nameBAX 855 (PEGYLATED RFVIII)
    D.3.9.4EV Substance CodeSUB90763
    D.3.10 Strength
    D.3.10.1Concentration unit IU international unit(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeRecombinant product with covalently bound polyethyleneglycol
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Severe hemophilia A (FVIII <1%)
    E.1.1.1Medical condition in easily understood language
    Hemophilia A
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.1
    E.1.2Level LLT
    E.1.2Classification code 10060612
    E.1.2Term Hemophilia A
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The co-primary objectives of the study are:
    1. To determine the safety of BAX 855 based of FVIII inhibitory antibody development
    2. To determine the efficacy of BAX 855 based on ABR as determined by
    development of spontaneous bleeds (bleeds not associated with trauma).
    E.2.2Secondary objectives of the trial
    - To determine the total ABR (spontaneous and traumatic bleeds)
    - To determine the rate of success of BAX 855 for treatment of breakthrough
    bleeding episodes
    - To characterize the success of BAX 855 for treatment of bleeding episodes
    based on the number of BAX 855 infusions needed for the treatment of a
    bleeding episode and through the length of intervals between bleeding episodes
    - To compare the total weight-adjusted consumption for prophylaxis and for the treatment of bleeding episodes
    - To assess Health-Related Quality of Life (HRQoL) over time for subjects
    receiving BAX 855.
    - To determine the safety of BAX 855, as assessed by occurrence of AEs and
    changes in vital signs and clinical laboratory parameters following BAX 855
    administration
    - To determine the immunogenicity of BAX 855
    - To assess patient satisfaction, patient activity levels, and health resource use
    over time for subjects receiving BAX 855
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects transitioning from other BAX855 trials:
    Subject has completed a previous BAX 855 study and is willing to
    immediately transition into this
    continuation study.i
    2. Subject is ≤ 75 years of age at screening of the previous BAX 855
    study.
    3. Subject continues to have a Karnofsky (for subjects aged ≥ 16 years)
    or Lansky (for subjects aged
    < 16 years) performance score of ≥ 60 (see Section 20.5).
    4. Subject is human immunodeficiency virus negative (HIV-); or HIV+
    with stable disease and
    CD4+ count ≥ 200 cells/mm3, as confirmed by central laboratory at
    screening.
    5. Subject is hepatitis C virus negative (HCV-) by antibody or PCR testing
    (if positive, antibody titer
    will be confirmed by PCR), as confirmed by central laboratory at
    screening; or HCV+ with
    chronic stable hepatitis.
    6. If female of childbearing potential, subject presents with a negative
    urine pregnancy test and
    agrees to employ adequate birth control measures for the duration of the
    study.
    7. Subject and/or legally authorized representative is willing and able to
    comply with the
    requirements of the protocol.
    Bax855 naive patients:
    Subject is ≤75 years of age at screening.
    2. Subject is naïve to BAX 855.
    3. Subject has severe hemophilia A (FVIII clotting activity < 1%) as
    confirmed by central laboratory
    at screening after at least a 72-hour washout period.ii
    4. Subject aged ≥ 6 years has documented previous treatment with
    plasma-derived FVIII
    concentrates or rFVIII for ≥ 150 EDs.
    5. Subject aged < 6 years has documented previous treatment with
    plasma-derived FVIII
    concentrates or rFVIII for ≥ 50 EDs.
    6. Subject is currently receiving prophylaxis or on-demand therapy with
    FVIII.
    Subject has a Karnofsky (for subjects aged ≥ 16 years) or Lansky (for
    subjects aged < 16 years)
    performance score of ≥ 60 (see Section 20.5).
    8. Subject is HIV-; or HIV+ with stable disease and CD4+ count ≥ 200
    cells/mm3, as confirmed by
    central laboratory at screening.
    9. Subject is HCV- by antibody or PCR testing (if positive, antibody titer
    will be confirmed by PCR),
    as confirmed by central laboratory at screening; or HCV+ with chronic
    stable hepatitis.
    10. If female of childbearing potential, subject presents with a negative
    urine pregnancy test and
    agrees to employ adequate birth control measures for the duration of the
    study.
    11. Subject and/or legally authorized representative is willing and able
    to comply with the
    requirements of the protocol.
    E.4Principal exclusion criteria
    Subjects transitioning from other BAX855 studies:
    Subject had detectable FVIII inhibitory antibodies (≥ 0.6 BU using the
    Nijmegen modification of
    the Bethesda assay) as confirmed by central laboratory at screening.
    2. Subject has developed FVIII inhibitory antibodies (≥ 0.6 BU using the
    Nijmegen modification of
    the Bethesda assay as determined at central laboratory in a previous
    BAX 855 study).
    3. Subject has acquired a hemostatic defect other than hemophilia A (eg,
    qualitative platelet defect or
    von Willebrand's disease) in a previous BAX 855 study.
    4. Subject has severe chronic hepatic dysfunction (eg, ≥ 5 times upper
    limit of normal alanine
    aminotransferase [ALT], as confirmed by central laboratory at
    screening).
    5. Subject has severe renal impairment (serum creatinine > 2.0 mg/dL),
    as confirmed by central
    laboratory at screening.
    6. Subject experienced a life-threatening or gastrointestinal bleeding
    episode within 3 months prior
    to study entry.
    7. Subject is scheduled to use other PEGylated drugs during study
    participation.
    8. Subject is planning to take part in any other clinical study during the
    course of the continuation
    study, with the exception of any other parallel BAX 855 study.
    9. Subject has medical, psychiatric, or cognitive illness or recreational
    drug/alcohol use that, in the
    opinion of the investigator, would affect subject safety or compliance.
    10. Subject is a family member or employee of the investigator.
    BAX855 naive patients:
    Subject has detectable FVIII inhibitory antibodies (≥ 0.6 BU using the
    Nijmegen modification of
    the Bethesda assay) as confirmed by central laboratory at screening.
    2. Subject has history of FVIII inhibitory antibodies (≥ 0.6 BU using the
    Nijmegen modification of
    the Bethesda assay or the Bethesda assay) at any time prior to
    screening.
    3. Subject has been diagnosed with an inherited or acquired hemostatic
    defect other than hemophilia
    A (eg, qualitative platelet defect or von Willebrand's disease).
    4. Subject has known hypersensitivity towards mouse or hamster
    proteins, PEG, or Tween 80.
    Subject has severe chronic hepatic dysfunction (eg, ≥ 5 times upper limit
    of normal ALT, as
    confirmed by central laboratory at screening).
    6. Subject has severe renal impairment (serum creatinine > 2.0 mg/dL),
    as confirmed by central
    laboratory at screening.
    7. Subject experienced a life-threatening or gastrointestinal bleeding
    episode within 3 months prior
    to study entry.
    8. Subject has current or recent (< 30 days) use of other PEGylated
    drugs prior to study participation
    or scheduled use of such drugs during study participation.
    9. Subject has participated in another clinical study involving an IP other
    than BAX 855 or device
    within 30 days prior to enrollment or is scheduled to participate in
    another clinical study involving
    an IP or investigational device during the course of this study.
    10. Subject has medical, psychiatric, or cognitive illness or recreational
    drug/alcohol use that, in the
    opinion of the investigator, would affect subject safety or compliance.
    11. Subject is a family member or employee of the investigator.
    E.5 End points
    E.5.1Primary end point(s)
    Safety: Development of inhibitoryantibodies to FVIII
    Efficacy: Spontaneous ABR
    E.5.1.1Timepoint(s) of evaluation of this end point
    All subjects will continue on study until a minimum of 100 EDs per subject have
    been achieved across all BAX 855 studies in which each subject participated.
    E.5.2Secondary end point(s)
    Efficacy
    1. Total ABR (spontaneous and traumatic bleeding episodes)
    2. Overall hemostatic efficacy rating of BAX 855 for treatment of
    breakthrough bleeding episodes
    3. Number of BAX 855 infusions to treat bleeding episodes
    4. Time intervals between bleeding episodes
    5. Weight-adjusted consumption of BAX 855
    Safety
    1. Occurrence of AEs and serious adverse events (SAEs)
    2. Changes in vital signs and clinical laboratory parameters (hematology,
    clinical chemistry, and
    lipids)
    3. Immunogenicity
    a. Binding antibodies (IgG and IgM) to FVIII, BAX 855, and PEG
    b. Anti-Chinese hamster ovary (CHO) antibodies
    Patient Reported Outcomes (PROs)
    Changes from baseline in parent study, if applicable, in the following:
    1. Bleed and pain severity as measured using the Haemo-SYM
    questionnaire
    2. Health-related quality of life (HRQoL) as assessed using the SF-
    36/PedsQL questionnaires
    E.5.2.1Timepoint(s) of evaluation of this end point
    All subjects will continue on study until a minimum of 100 EDs per subject have
    been achieved across all BAX 855 studies in which each subject participated.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    parallel design
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA50
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Austria
    Belgium
    Bulgaria
    Canada
    Czech Republic
    Germany
    Hong Kong
    Israel
    Japan
    Korea, Republic of
    Lithuania
    Malaysia
    Netherlands
    Poland
    Romania
    Russian Federation
    Serbia
    Spain
    Sweden
    Switzerland
    Taiwan
    Thailand
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 120
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 2
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 58
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 60
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 80
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 50
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 159
    F.4.2.2In the whole clinical trial 200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Continue with the expected normal treatment for Hemophilia A
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-10-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-03-27
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2018-03-02
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA